1. Cardno A.G., Gottesman I.I. Twin studies of schizophrenia: from bow-and-arrow concordances to star war mx and functional genomics//Amer. J. Med. Genetics. 2000. Vol. 97, N 1. P. 12 - 17.

2. Lichtenshtein P., Yip B.H., Bjork C. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study//Lancet. 2009. Vol. 373, N 9659. P. 234 - 239.

3. Gottesman I.I., Laursen T.M., Bertelsen A et al. Severe mental disorders in off-springs with 2 psychiatrically ill parents//Arch. Gen Psychiatry. 2010. Vol. 67, N 3. P. 252-257.

4. Os van J., Kenis G., Rutten B.P. The environment and schizophrenia//Nature. 2010. Vol. 11, N 468 (7321). P. 203 - 212.

5. Os van J., Kapur S. Schizophrenia//Lancet. 2009. Vol. 374. P. 635 - 645.

6. Fusar-Poli P., Tantardini M., De Simone S., Ramella-Cravaro V., Oliver D., Kingdon J., Kotlicka-Antczak M., Valmaggia L., Lee J., Millan M.J., Galderisi S., Balottin U., Ricca V., McGuire P. Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk//Eur. Psychiatry. 2017. Vol. 40. P. 65 - 75.

7. Popovic D., Schmitt A., Kaurani L., Senner F., Papiol S., Malchow B., Fischer A., Schulze T.G., Koutsouleris N., Falkai P. Childhood trauma in schizophrenia: Current findings and research perspectives//Front. Neurosci. 2019. Vol. 13. P. 274.

8. Dickerson F., Severance E., Yolken R. The microbiome, immunity, and schizophrenia and bipolar disorder//Brain Behav. Immun. 2017. Vol. 62. P. 46 - 52.

9. Kahn R.S., Sommer I.E. The neurobiology and treatment of first-episode schizophrenia//Mol. Psychiatry. 2015. Vol. 20. P. 84 - 97.

10. Haijma S.V., Van Haren N., Cahn W, Koolschijn P.C., Hulshoff Pol H.E., Kahn R.S. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects//Schizophr. Bull. 2013. Vol. 39. P. 1129 - 1138.

11. Карлссон А., Лекрубье И. Дофаминовая теория патогенеза шизофрении. Руководство для врачей / Ред. Мосолов С.Н. - Лондон, 2004.

12. McGrath J., Saha S., Welham, J. A systematic review of the incidence of schizophrenia//B. M. C. Med. 2004. Vol. 2. P. 13.

13. Saha S., Chant D., Welham J., McGrath, J. A systematic review of the prevalence of schizophrenia//PLoS Med. 2005. Vol. 2. P. 413 - 433.

14. Tandon R., Keshavan M.S., Nasrallah H.A. Shizophrenia, "Just the facts": What we know in 2008. 2. Epidemiology and etiology//Schizophr. Res. 2008. Vol. 102. P. 1 - 18.

15. Демчева Н.К., Яздовская А.В., Михайлов В.И. Анализ первичной заболеваемости психическими расстройствами в РФ в 2016 году//Вестник неврологии, психиатрии и нейрохирургии. 2017. N 10. С. 25 - 35.

16. Демчева Н.К., Яздовская А.В., Николаева Т.А. Структурный анализ общей заболеваемости психическими расстройствами в Российской Федерации в 2016 - 2018 годах//Вестник неврологии, психиатрии и нейрохирургии. 2019. N 6. С. 4 - 15.

17. Кекелидзе З.И. Казаковцев Б.А. (ред.). Эпидемиологические показатели деятельности психиатрических служб Российской Федерации (2005 - 2013 гг.). М.: ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России, 2015; 572 с.

18. Шмуклер А.Б., Бочкарева О.С. Отдаленный катамнез больных шизофренией и расстройствами шизофренического спектра после первого обращения в психоневрологический диспансер//Социальная и клиническая психиатрия. 2012. Т. 22, N 2. С. 10 - 15.

19. Mamakou V., Thanopoulou A., Gonidakis F., Tentolouris N., Kontaxakis V. Schizophrenia and type 2 diabetes mellitus//Psychiatriki. 2018. Vol. 29, N 1. P. 64 - 73.

20. Emul M., Kalelioglu T. Etiology of cardiovascular disease in patients with schizophrenia: current perspectives//Neuropsychiatr. Dis. Treat. 2015. Vol. 11. P. 2493 - 2503.

21. Hayes J.F., Marston L., Walters K., King M.B., Osborn D.P.J. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014//Br. J. Psychiatry. 2017. Vol. 211. N 3. P. 175 - 181.

22. Sher L., Kahn R.S. Suicide in schizophrenia: An educational overview//Medicina. 2019. Vol. 55, N 7. P. 1 - 11.

23. Larson M.K., Walker E.F., Compton M.T. Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders//Expert. Rev. Neurother. 2010. Vol. 10. N 8. P. 1347 - 1359.

24. Zdanowicz N., Mees L., Jacques D., Tordeurs D., Reynaert C. Assessment and treatment of the risk of psychosis in adolescents - a review//Psychiatr. Danub. 2014. Vol. 26. N 2. P.115 - 121.

25. Van Harren N.E.M., Cahn W., Hulshoff Pok H.E., Kahn R. Schizophrenia as a progressive brain disease//Eur Psychiatry. 2008. Vol. 23. P. 245 - 254.

26. Correll C.U., Hauser M., Auther A.M, Cornblatt B.A. Research in people with psychosis risk syndrome: a review of the current evidence and future directions//J. Child Psychol. Psychiatry. 2010. Vol. 51. N 4. P. 390 - 431.

27. Suvisaari J., Mantere O., Kein nen J., M ntyl T., Rikandi E., Lindgren M., Kiesepp T., Raij T.T. Is It Possible to Predict the Future in First-Episode Psychosis?//Front Psychiatry. 2018. Vol. 9. P. 1 - 15.

28. Andreasen N.C., Carpenter W.T. Jr, Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus//Am. J. Psychiatry. 2005. Vol. 162. N 3. P. 441 - 449.

29. Emsley R., Chiliza B., Asmal L., Lehloenya K. The concepts of remission and recovery in schizophrenia//Curr. Opin. Psychiatry. 2011. Vol. 24, N 2. P. 114 - 121.

30. Краснов В.Н., Гурович И.Я., Мосолов С.Н., Шмуклер А.Б. с соавт. Психиатрическая помощь больным шизофренией. Клиническое руководство/Под редакцией В.Н. Краснова, И.Я. Гуровича, С.Н. Мосолова, А.Б. Шмуклера. Москва, 2007. (2-е издание).

31. Психиатрия: Национальное руководство/Коллективная монография. Под ред. Александровского Ю.А., Незнанова Н.Г./ - 2-е издание, переработанное и дополненное. Москва. 2018.

32. Upthegrove R., Marwaha S., Birchwood M. Depression and schizophrenia: Cause, consequence, or trans-diagnostic issue?//Schizophr. Bull. 2017. Vol. 43, N 2. P. 240 - 244.

33. Radanovic M., Sousa R.T., Valiengo L., Gattaz W.F., Forlenza O.V. Formal thought disorder and language impairment in schizophrenia//Arq. Neuropsiquiatr. 2013. Vol. 71, N 1. P. 55 - 60.

34. Roche E., Creed L., MacMahon D., Brennan D., Clarke M. The epidemiology and associated phenomenology of formal thought disorder: A systematic review//Schizophr. Bull. 2015. Vol. 41, N 4. P. 951 - 962.

35. Карякина М.В., Сидорова М.Ю., Шмуклер А.Б. Нарушения речи у больных шизофренией//Социальная и клиническая психиатрия. 2017. Т. 27, N 4. С. 93 - 100.

36. Hor K., Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors//J. Psychopharmacol. 2010. Vol. 24, Suppl. 4. P. 81 - 90.

37. Volavka J. Violence in schizophrenia and bipolar disorder//Psychiatr. Danub. 2013. Vol. 25, N 1. P. 24 - 33.

38. Wible C.G., Preus A.P., Hashimoto R. A cognitive neuroscience view of schizophrenic symptoms: abnormal activation of a system for social perception and communication//Brain Imaging Behav. 2009. Vol. 3, N 1. P. 85 - 110.

39. Авруцкий Г.Я., Недува А.А. Лечение психически больных. - 2-е изд. - М.: Медицина, 1988. - 528 с.

40. Мосолов С.Н. Основы психофармакотерапии. - М.: Восток, 1996. - 288 с.

41. Мосолов С.Н., Цукарзи Э.Э. Психофармакотерапия шизофрении//Психиатрия: национальное руководство/под ред. Н.Г. Незнанова, Ю.А. Александровского. - М.: Гэотар-медиа, 2018. С. 299 - 328.

42. Мосолов С.Н., Цукарзи Э.Э., Алфимов П.В. Алгоритмы биологической терапии шизофрении//Современная терапия психических расстройств. - 2014. - N 1. - С. 27 - 36.

43. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance//World J Biol Psychiatry. - 2012. - Vol. 13 (5). - P. 318 - 378.

44. Фалкаи П., Воброк Т., Либерман Д. с соавт. Рекомендации Всемирной федерации обществ биологической психиатрии по биологической терапии шизофрении. Часть 1. Лечение острого периода шизофрении//Современная терапия психических расстройств, 2011, 1, с. 5 - 25.

45. Хасан А., Фалкаи П., Воброк Т. с соавт. Руководство по биологической терапии шизофрении Всемирной федерации обществ биологической психиатрии (WFSBP). Часть 1. Терапия острого приступа шизофрении и терапевтически резистентных случаев //Современная терапия психических расстройств, Тематический выпуск 1, 2014, с. 3 - 40.

46. Мосолов С.Н., Цукарзи Э.Э., Капилетти С.Г. Антипсихотическая фармакотерапия шизофрении: от научных данных к клиническим рекомендациям//В сборнике: Биологические методы терапии психических расстройств. Под ред. Мосолова С.Н. Доказательная медицина - клинической практике. Москва, 2012. С. 11 - 61.

47. Джонс П.Б., Бакли П.Ф. Шизофрения/Клиническое руководство (перевод с английского)/под общей редакцией С.Н. Мосолова. Москва, 2008.

48. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005 May; 162 (5): 947-53

49. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003 Aug; 160 (8): 1396-404.

50. Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004 Jun; 161 (6): 985-95.

51. Dixon L.B., Perkins B., Calmes C. Guideline watch (September 2009): Practice Guideline for the treatment of patients with schizophrenia, 2009.

52. NICE. Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). London, 2010.

53. Johnsen E., Jorgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials //BMC Psychiatry, 2008, Vol. 8, p. 31.

54. Rabinowitz J., Levine S., Barkai O., et al. Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. Schizophrenia Bulletin. 2009. vol. 35 no. 4 pp. 775 - 788.

55. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Ba ckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939-51 Published Online July 11, 2019 http://dx.doi.org/10.1016/ S0140-6736(19) 31135-3.

56. Tandon R., Moller H.J., Belmaker R.H. et al. World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia //Schizophr. Res., 2008, Vol. 100, p. 20 - 38.

57. Филилеева О.В., Мосолов С.Н. Эквивалентные дозировки антипсихотических препаратов. Современная терапия психических расстройств. - 2019. - N 3. - С. 36 N 44 DOI: 10.21265/PSYPH.2019.49.35981.

58. Fleischhacker W.W., McQuade R.D., Marcus R.N. et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia//Biol Psychiatry. - 2009. - Vol. 65 (6). - P. 510-517. 31.

59. Citrome L., Reist C., Palmer Let. et al. Impact of real world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder//Schizophr Res. - 2009. - Vol. 115 (2-3). - P. 115 - 120.

60. Simpson G.M., Mahmoud R.A., Lasser R.A. et al. A 1year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder//J Clin Psychiatry. - 2006. - Vol. 67 (8). - P. 1194 - 1203. 38.

61. Zimbroff D.L., Kane J.M., Tamminga С.A. et al. Controlled, dose-rcsponse study of sertindole and haloperidol in the treatment of schizophrenia//Am J Psychiatry. - 1997. - Vol. 154. - P. 782 - 791.

62. Leucht S., Corves C., Arbter D., Engel R., Li C., Davis J. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. //Lancet, 2009, Vol. 373, p. 31 - 41.

63. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: A prospective, randomized study. Am J Psychiatry, 2015, 172: 52 - 58.

64. Pompili M., Lester D., Dominici G. et al. Indications for electroconvulsive treatment in schizophrenia: a systematic review//Schizophr Res. - 2013. - Vol. 146 (1-3). - P. 1 - 9.

65. Tharyan P., Adams C. Electroconvulsive therapy for schizophrenia.//Cochrane Database Syst Rev. 2005; (2): CD000076. doi: 10.1002/14651858.CD000076.pub2.

66. Оленева Е.В., Цукарзи Э.Э., Мосолов С.Н. Комбинированное применение ЭСТ и атипичных антипсихотиков у больных шизофренией, резистентных к терапии//Социальная и клиническая психиатрия. - 2007. - Т. 17, N 4. - С. 28 - 32.

67. Oleneva E.V., Tsukarzi E.E., Mosolov S.N. Combined olanzapine - ECT therapy for resistant schizophrenia//International Journal of Neuropsychopharmacology. - 2008. - Vol. 11, No. S1. - P. S151.

68. Оленева Е.В. Комбинированное применение ЭСТ и атипичных антипсихотиков дибензодиазепинового ряда при терапевтически резистентной шизофрении: дисс. канд. мед. наук. М., 2010.

69. Grover S., Hazari N., Kate N. Combined use of clozapine and ECT: a review//Acta Neuropsychiatr. - 2015, Jun. - Vol. 27 (3). - P. 131 - 142.

70. Maslenikov N., Tsukarzi E., Mosolov S. Repetitive Transcranial Magnetic Stimulation (rTMS) for the treatment of depression in schizophrenia patients//Ann Gen Psychiatry. - 2008. - Vol. 7, Suppl. 1. - S. 312.

71. Маслеников Н.В., Цукарзи Э.Э., Мосолов С.Н. Эффективность транскраниальной магнитной стимуляции при депрессиях у больных шизофренией//Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. - 2010. - N 2. - С. 14 - 18.

72. Маслеников Н.В., Цукарзи Э.Э., Мосолов С.Н. Транскраниальная магнитная стимуляция (ТМС) в лечении депрессии и негативной симптоматики при шизофрении//Психическое здоровье. - 2013. - Т. 11, N 1 (80). - С. 39 - 44.

73. Wobrock T., Guse B., Cordes J. et al. Left prefrontal high-frequency rTMS for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicentre trial//Biol Psychiatry. - 2015, Jun 1. - Vol. 77 (11). - P. 979 - 988.

74. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007; 33: 1013-1022.

75. Kirpatrick B, Strauss G, Nguen L, Fischer B, Daniel D, Cienfuegos A, Marder S. The Brief Negative Symptom Scale: Psychometric Properties. Schizophr Bull 2011 Mar; 37(2): 300 - 305.

76. Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018; 268(7): 625-639.

77. N meth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103-1113.

78. Corponi F, Serretti A, Montgomery S, Fabbri C. Cariprazine specificity profile in the treatment of acute schizophrenia: a meta-analysis and meta-regression of randomized-controlled trials. Int Clin Psychopharmacol. 2017; 32(6): 309-318.

79. Levine SZ, Leucht S. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophr Res. 2014; 156 (1): 107-114.

80. Kumar S, Chaudhury S. Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: an open-label clinical study. Ind Psychiatry J. 2014; 23(1): 27-35.

81. Riedel M, Muller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6): 432-437.

82. Lindenmayer JP, Khan A, Iskander A, et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007; 68(3): 368-379.

83. Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016; 173(9): 876-886.

84. Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res. 2005; 80(1): 85-97.

85. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book//Biol. Psychiatry, 2004, Vol. 55, p. 1013 - 1022.

86. Harvey PD, Rabinowitz J, Eerdekens M, et al. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005 Oct; 162 (10): 1888-95.

87. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007 Jul; 164 (7): 1061-71.

88. Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci. 2006 Nov; 31(6): 369 - 376.

89. van Rooijen G, Vermeulen JM, Ruhe HG, de Haan L. Treating depressive episodes or symptoms in patients with schizophrenia.//CNS Spectrums, 2018, P. 1 - 10. doi: 10.1017/S1092852917000554.

90. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia//Schizophr Bull. - 2009. - Vol. 35 (2). - P. 383 - 402.

91. Addington D, Addington J, Maticka-Tyndale E, Joyce J Reliability and validity of depression rating scale for schizophrenics. Schizophr Res. 1992 Mar; 3(3): 201-208.

92. Lako I.M., Bruggeman R., Knegtering H. et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia//J Affect Disord. - 2012. - Vol. 140 (1). - P. 38-47.6.

93. Мазо Г.Э. Влияние депрессии на течение шизофрении//Психиатрия и психофармакотерапия. - 2006. - Т. 8, N 3. - С. 22 - 24.

94. Мазо Г.Э., Горбачев С.Е. Депрессия при шизофрении: опыт и подходы практических врачей к диагностике и терапии//Социальная и клиническая психиатрия. - 2009. - N 4. - С. 5 - 14.

95. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. Изд. 2-е, доп. - СПб.: Ладога, 2013. - 372 с.

96. Мазо Г.Э. Депрессия при шизофрении: механизмы формирования//Науч.-практ. конф. "Психическое здоровье: социальные, клинико-организационные и научные аспекты": сб. матер./под ред. Г.П. Костюка. - М., 2017. - С. 327 - 334.

97. M ller H.J. Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues//World J Biol Psychiatry. - 2005. - Vol. 6 (4). - P. 247 - 263.

98. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review.//Acta Psychiatr Scand. 2002; 106(2): 83 - 96.

99. Abuzzahab F.S. Sr., Zimmerman R.L. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia//J Clin Psychiatry. - 1982. - Vol. 43 (3). - P. 105 - 110.

100. Krakowski M., Czobor P., Volavka J. Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes//Psychiatry Res. - 1997. - Vol. 71 (1). - P. 19 - 26.

101. Mauri M.C., Bitetto A., Fabiano L. et al. Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs//Prog Neuropsychopharmacol Biol Psychiatry. - 1999. - Vol. 23 (1). - P. 43 - 54.

102. Bermanzohn P.C., Siris S.G. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia//Compr Psychiatry. - 1992, Jul-Aug. - Vol. 33 (4). - P. 221 - 232.

103. Van Putten T., May R.P. "Akinetic depression" in schizophrenia//Arch Gen Psychiatry. - 1978. - Vol. 35 (9). - P. 1101 - 1107.

104. Riedel M., Mayr A., Seemuller F. et al. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol//World J Biol Psychiatry. - 2012. - Vol. 13 (1). - P. 30 - 38.

105. Alfredsson G., Harnryd C., Wiesel F.A. Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations -- Psychopharmacology (Berlin). - 1984. Vol. 84 (2). - P. 237 - 241.

106. Falkai P., Wobrock T., Lieberman J. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 2: long-term treatment of schizophrenia//World J Biol Psychiatry. - 2006. - Vol. 7 (1). - P. 5-40.

107. Furtado V.A., Srihari V. Atypical antipsychotics for people with both schizophrenia and depression//Cochrane Database Syst Rev. 2008. Vol. 1. CD005377.

108. Маслеников Н.В., Цукарзи Э.Э., Мосолов С.Н. Алгоритм биологической терапии депрессии при шизофрении. Современная терапия психических расстройств. - 2019. - N 1. - С. 31 - 39.

109. Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol.//European Neuropsychopharmacology. 2001; 11(3): 264.

110. Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006 Dec; 21 (8): 523-30.

111. Nasrallah H.A., Cucchiaro J.B., Mao Y. et al. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies//CNS Spectr. - 2015, Apr. - Vol. 20 (2). - P. 140 - 147.

112. Kim S.W., Shin I.S., Kim J.M. et al. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial//Prog Neuropsychopharmacol Biol Psychiatry. - 2007. - Vol. 31 (7). - P. 1504-1509.

113. Addington DE, Mohamed S, Rosenheck RA, et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.//J Clin Psychiatry. 2011; 72(1): 75 - 80.

114. Мосолов С.Н. Основы психофармакотерапии. Москва. Восток. 1996, 242 с.

115. Nelson J.C., Bowers M.B. Jr., Sweeney D.R. Exacerbation of psychosis by tricyclic antidepressants in delusional depression//Am J Psychiatry. - 1979. - Vol. 136 (4B). - P. 574 - 576.

116. Whitehead C., Moss S., Cardno A., Lewis G. Antidepressants for the treatment of depression in people with schizophrenia: a systematic review//Psychol Med. - 2003. - Vol. 33 (4). - P. 589 - 599.

117. Мосолов С.Н. Клиническое применение современных антидепрессантов. С.-П., "Медицинское информационное агентство", 1995, 568 с.

118. Mulholland C., Lynch G., King D.J., Cooper S.J. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia//J Psychopharmacol. - 2003. - Vol. 17 (1). - P. 107 - 112.

119. Addington D., Addington J., Patten S. et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia//J Clin Psychopharmacol. - 2002. - Vol. 22 (1). - P. 20 - 25.

120. Kirli S., Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia//Schizophr Res. - 1998. - Vol. 33 (1-2). - P. 103 - 111.

121. Zisook S., Kasckow J.W., Lanouette N.M. et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial//J Clin Psychiatry. - 2010. - Vol. 71 (7). - P. 915 - 922.

122. Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation//World J Biol Psychiatry. - 2015, Apr. - Vol. 16 (3). - P. 142 - 170.

123. Mazeh D., Shahal B., Saraf R., Melamed Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia//J Clin Psychopharmacol. - 2004. - Vol. 24 (6). - P. 653 - 655.

124. Terevnikov V., Stenberg J.H., Tiihonen J. et al. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase//Hum Psychopharmacol. - 2011. - Vol. 26 (3). - P. 188 - 193.

125. Englisch S., Morgen K., Meyer-Lindenberg A., Zink M. Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature//Clin Neuropharmacol. - 2013. - Vol. 36 (6). - P. 203 - 215.

126. Plasky P. Antidepressant usage in schizophrenia//Schizophr Bull. - 1991. - Vol. 17 (4). - P. 649 - 657.

127. Siris S.G., Bermanzohn P.C., Mason S.E., Shuwall M.A. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial//Arch Gen Psychiatry. - 1994. - Vol. 51 (2). - P. 109 - 115.

128. Prusoff B.A., Williams D.H., Weissman M.M., Astrachan B.M. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine//Arch Gen Psychiatry. - 1979. - Vol. 36 (5). - P. 569 - 575.

129. Lefaucheur J.P., Andre-Obadia N., Antal A. et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)//Clin Neurophysiol. - 2014. - Vol. 125 (11). - P. 2150 - 2220.

130. Оленева Е.В., Цукарзи Э.Э., Мосолов С.Н. Комбинированное применение ЭСТ и атипичных антипсихотиков у больных шизофренией, резистентных к терапии//Социальная и клиническая психиатрия. - 2007. - Т. 17, N 4. - С. 28 - 32.

131. Altamura A.C., Bassetti R., Bignotti S. et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study//Schizophr Res. - 2003. - Vol. 60 (1). - P. 47 - 55.

132. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination.//Arch Gen Psychiatry. 2005; 62(3): 247 - 253.

133. Harvey PD, Espaillat S. Suicide in schizophrenia. In Koslow SH, Ruiz P, Nemeroff CB, eds. A Concise Guide to Understanding Suicide Epidemiology: Pathophysiology and Prevention, 1st ed.. Cambridge: Cambridge University Press; 2014: 406.

134. Цукарзи Э.Э. Суицид: оценка рисков и первая помощь//Современная терапия психических расстройств., 2011, N 2, 30 - 39.

135. Meltzer H.Y. Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine//J Clin Psychiatry. - 2005. - Vol. 66 (4). - P. 530 - 533.

136. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis.//Schizophr Res. 2005; 73(2-3): 139 - 145.

137. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia.//Arch Gen Psychiatry. 2003; 60(1): 82 - 91.

138. Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ. Lithium for schizophrenia (Review).//Cochrane Database Syst Rev. 2015; 10): CD003834. doi: 10.1002/14651858.CD003834.pub3.

139. Цукарзи Э.Э. Неотложная помощь при агрессивном поведении. Часть II. Ведение пациентов//Ж. Современная терапия психических расстройств., 2013, N 2, с. 31 - 40.

140. Gaynes BN, Brown C, Lux LJ, et al. Strategies to De-escalate Aggressive Behavior in Psychiatric Patients. AHRQ Comparative Effectiveness Reviews. Report no. 16-EHC032-EF. 2016, Rockville, MD: Agency for Healthcare Research and Quality.

141. Putkonen A, Kuivalainen S, Louheranta O, et al. Cluster-randomized controlled trial of reducing seclusion and restraint in secured care of men with schizophrenia. Psychiatr Serv 2013, 64: 850 - 855.

142. Lim HK, Kim JJ, Pae CU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study. Neuropsychobiology, 2010, 62: 81 - 86.

143. Simpson JR, Thompson CR, Beckson M. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion and restraint in an acute inpatient psychiatric setting. J Clin Psychopharmacol, 2006, 26: 333 - 335.

144. Taylor D, Okocha C, Paton C, et al. Buccal midazolam for agitation on psychiatric intensive care wards. Int J Psychiatry in Clin Prac, 2008, 12: 309 - 311.

145. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: Multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry, 2011, 198: 51 - 58.

146. Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract, 2006; 12 (1): 30 - 40.

147. Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32: 405 - 413.

148. Pasin L, Landoni G, Nardelli P, et al. Dexmedetomidine reduces the risk of delirium, agitation and confusion in critically Ill patients: A meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth, 2014, 28: 1459 - 1466.

149. Martel M, Sterzinger A, Miner J, et al. Management of acute undifferentiated agitation in the emergency department: A randomized double-blind trial of droperidol, ziprasidone, and midazolam. Acad Emerg Med, 2005,12: 1167 - 1172.

150. Nobay F, Simon B, Levitt A, et al. A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients. Acad Emerg Med, 2004, 11: 744 - 749.

151. Taylor DM, Yap CY, Knott JC, et al. Midazolam-droperidol, droperidol, or olanzapine for acute agitation: A randomized clinical trial. Ann Emerg Med, 2017, 69: 318 - 326.

152. Veser FH, Veser BD, McMullan JT, et al. Risperidone versus haloperidol, in combination with lorazepam, in the treatment of acute agitation and psychosis: A pilot, randomized, double-blind, placebo-controlled trial. J Psychiatr Pract, 2006, 12: 103 - 108.

153. Wilson MP, MacDonald K, Vilke GM, et al. A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation. J Emerg Med, 2012, 43: 790 - 797.

154. Suzuki H, Takahashi Y. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intrаmuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol, 2014, 29: 83 - 88.

155. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology, 2002, 26: 494 - 504.

156. Ostinelli EG, Jajawi S, Spyridi S, et al. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev, 2018, 1: CD 008074.

157. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: Efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol, 2007, 27: 171 - 176.

158. Mantovani C, Labate CM, Sponholze AJ, et al. Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions. J Clin Psychopharmacol, 2013, 33: 306 - 312.

159. Chouinard G, Annable L, Turnier L, et al. A double-blind randomised clinical trial of rapid tranquillisation with IM clonazepam and IM haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry, 1993, 38 (Suppl 4): S114-121.

160. Ostinelli EG, Brooke-Powney MJ, Li X, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev, 2017, 7: CD009377.

161. Knott JC, Taylor DM and Castle DJ Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med, 2006, 47: 61 - 67.

162. Yap CY, Taylor DM, Knott JC, et al. Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: Subgroup analysis of a randomized controlled trial. Addiction, 2017, 112: 1262 - 1269.

163. Isbister G, Calver L, Page C, et al. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: The DORM study. Ann Emerg Med, 2010, 56: 392 - 401.

164. Chan EW, Taylor DM, Knott JC, et al. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Emerg Med, 2013, 61: 72 - 81.

165. Scheppke KA, Braghiroli J, Shalaby M, et al. Prehospital use of IM ketamine for sedation of violent and agitated patients. West J Emerg Med, 2014, 15: 736 - 741.

166. Reade MC, O"Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009; 13(3): R75. Epub 2009 May 19.

167. Blumer D. Catatonia and the neuroleptics: Psychobiologic significance of remote and recent findings //Comp. Psychiatry, 1997; Vol. 38; N 4; p. 193 - 201.

168. Volz A., Khorsand V., Gillies D. et al. Benzodiazepins for schizophrenia //Cochrane database Syst. Rev., 2007, CD006391.

169. Wolkowitz D.M/. Pickar D. Benzodiazepine in the treatment of schizophrenia: a review and reappraisal //Am. J. Psychiatry, 1991, Vol. 148, p. 714 - 726.

170. Дедкова А.Е. Опыт эффективного применения бензодиазепинов при кататонии, осложненной злокачественным нейролептическим синдромом (клиническое наблюдение). Современная терапия психических расстройств 2016, N 2, 29 - 34.

171. Luchini F, Medda P, Mariani MG, et al. (2015) Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World J Psychiatry 22: 182 - 192.

172. Хасан А., Фалкаи П., Воброк Т. с соавт. Руководство по биологической терапии шизофрении Всемирной федерации обществ биологической психиатрии (WFSBP). Часть 2. Длительная терапия шизофрении и тактика ведения пациентов с индуцированными антипсихотическими препаратами побочными эффектами//Современная терапия психических расстройств, Тематический выпуск 2, 2014, с. 2 - 36.

173. Kishimoto T., Agarwal V., Kishi T., Leucht S. et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second generation antipsychotics versus first-generation antipsychotics//Mol. Psychiatry, 2011, Vol. 12, p. 432 - 436.

174. Peterson K., Carson S., McDonagh M. et al. Drug Class Review. Atypical Antipsychotic Drugs 2010. Oregon Health & Science University Portland, Oregon Final Update, July 2010.

175. Uchida H., Suzuki T., Takeuchi H. et al. Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin, 2011, vol. 37 no. 4 pp. 788 - 799.

176. Pandina G.J., Lindenmayer J.P., Lull J. et al. А randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia//J Сlin Psychopharmacol. - 2010. - Vol. 30 (3). - P. 235 - 244.

177. Juckel G., de Bartolomeis A., Gorwood Ph. et al. Towards a framework for treatment effectiveness in schizophrenia//Neuropsychiatric Disease and Treatment. - 2014. - No. 10. - P. 1867 - 1878.

178. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000; 101: 323-329.

179. Rummel-Kluge C., Komossa K., Leucht, S. et al. Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. Schizophrenia Bulletin, 2012. vol. 38 no. 1 pp. 167 - 177.

180. Rummel-Kluge C., Komossa K., Leucht, S. et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010 November; 123(2-3): 225 - 233.

181. Мосолов С.Н., Потапов А.В., Цукарзи Э.Э. Стандартизированные клинико-функциональные критерии ремиссии при шизофрении. Методические рекомендации МЗ РФ, Москва, 2018, 68 с.

182. Prosser A., Helfer B., Leucht S. Biological v. psychosocial treatment: a myth about pharmacotherapy v. psychotherapy//Br. J. Psychiatr. 2016. Vol.208. P. 209 - 211.

183. Norman R., Lecomte T., Addington D., Anderson E. Canadian Treatment Guidelines on Psychosocial Treatment of Schizophrenia in Adults//Can. J. Psychiatr. 2017. Vol. 62, N 9. P. 617 - 623.

184. Isaac C., Januel D. Neural correlates of cognitive improvements following cognitive remediation in schizophrenia: a systematic review of randomized trials//Socioaffect. Neurosci. Psychol. 2016. Vol. 6. P. 1 - 18.

185. Health Quality Ontario. Cognitive behavioural therapy for psychosis: a health technology assessment//Ont. Health Technol. Assess. Ser. [Internet]. 2018. Vol. 18, N 5. P. 1 - 141.

186. Turner D.T., McGlanaghy E., Cuijpers P., van der Gaag M., Karyotaki E., MacBeth A. Meta-Analysis of Social Skills Training and Related Interventions for Psychosis//Sch. Bul. 2018. Vol. 44, N 3. P 475 - 491.

187. Frank N. Cognitive remediation for patients with schizophrenia//Ann. Med. Psycholol. 2007. Vol. 165, N 3. P. 187 - 190.

188. Keefe R.S., Vinogradov S., Medalia A. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia//Schizophr. Bull. 2011. Vol. 37, N 5. P. 1057 - 1065.

189. Subramaniam K., Luks T.L., Garrett C. Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains//Neuroimage. 2014. Vol. 99. P. 281 - 292.

190. Kaneko K. Negative symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning//Yonago Acta Med. 2018. Vol. 61, N 2. P. 91 - 102.

191. Tripathi А., Kar S.K., Shukla R. Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies//Clin. Psychopharmacol. Neurosci. 2018. Vol. 16, N 1. P. 7 - 17.

192. Иванов М.В., Незнанов Н.Г. Негативные и когнитивные расстройства при эндогенных психозах: диагностика, клиника, терапия. - СПб.: Изд. НИПНИ им. В.М. Бехтерева, 2008. 288 с.

193. Дорофейкова М.В. Когнитивные нарушения и клинико-лабораторные характеристики у больных шизофренией//Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2017. N 1. С. 38 - 43.

194. Meesters P.D., Stek M.L., Comijs Y.C. Social functioning among older community-dwelling patient with schizophrenia: a review//Am. J. Psychiatry. 2010. Vol. 18, N 10. P. 862 - 878.

195. Jain M., Singh S., Dalal P. A cross-sectional study of cognitive functions and disability in schizophrenia from a tertiary care hospital in North India//Med. J. DY Patil. Univ. 2016. Vol. 9. P. 457 - 464.

196. Prouteau A., Verdoux H., Briand C. Cognitive predictions of psychosocial functioning outcome in schizophrenia: a follow-up subjects participating in a rehabilitation program//Schizophr. Res. 2005. Vol. 77. P. 343 - 353.

197. Wykes T., Huddy V., Cellard C. A meta-analysis of cognitive remediation in schizophrenia: methodology and effect sizes//Am. J. Psychiatry. 2011. Vol. 168, N 5. P. 472 - 487.

198. Fett A.K., Viechtbauer W., Dominquez M.P. The relationship between neurogognition and social cognition with functional outcomes in schizophrenia: a meta-analysis//Neurosci. Biobehav. Rev. 2011. Vol. 35. P. 573 - 588.

199. Brekke J., Kay D.D., Lee K.S. Biosocial pathways to social outcome in schizophrenia: a path analytic model//Schizophr. Res. 2005. Vol. 80. P. 213 - 225.

200. Jaramillo P., Fuentes I., Ruiz I., Ruiz J.C. Cognition, social cognition and social functioning in schizophrenia//Psychology, Society & Education. 2009. Vol. 1, N 1. P. 13 - 24.

201. Savla G.N., Vell L., Armstrong C.C. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence//Schizophr. Bull. 2013. Vol. 39, N 5. P. 979 - 992.

202. Deckler E., Hodgins G.E., Pinkham A.E. Social cognition and neurocognition in schizophrenia and healthy controls: intercorrelation of performance and effects of manipulations aimed at increasing task difficulty//Front. Psychiatry. 07 Aug. 2018. DOI: 10.3389/fpsyt.2018.00356.

203. Kurtz M.M., Mueser K.T. A meta-analysis of controlled research of social skills training for schizophrenia//J. Consult. Clin. Psychol. 2008. Vol. 76, N 3. P. 491 - 504.

204. Kurtz M.M., Richardson Ch.L. Social cognitive training for schizophrenia: A meta-analytic investigation of controlled research//Shizophr Bull. 2012. Vol. 38, N 5. P. 1092 - 1104.

205. Pekkala E., Merinder L. Psychoeducation for schizophrenia//The Cochrane Database of Systematic Reviews. 2002.

206. Lincoln T.M., Wilhelm K., Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis//Schizophr. Res. 2007. Vol. 96. P. 232 - 245.

207. Lincoln T. M., Rief W., Westermann S. Who stays, who benefits? Predicting dropout and change in cognitive behaviour therapy for psychosis//Psychiatr. Res. 2014. Vol. 216, N 2. P. 198 - 205.

208. Xia J., Merinder L.B., Belgamwar M.R. Psychoeducation for schizophrenia//The Cochrane Database of Systematic Reviews. 2011.

209. Zhao S., Sampson S., Xia J., Jaram M.B. Psychoeducation (brief) for people with serious mental illness//The Cochrane Database of Systematic Reviews. 2015.

210. Zimmermann G., Favrod J., Trieu V.H., Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis//Schizophrenia Research. 2005. Vol. 77, N 1. P. 1 - 9.

211. Hazell C.M. Hayward M., Cavanagh K., Strauss C. A systematic review and meta-analysis of low intensity CBT for psychosis//Clin. Psychol. Rev. 2016. Vol. 45. P. 183 - 192.

212. Naeem F. Khoury B., Munshi T., Ayub M. Brief Cognitive Behavioral Therapy for Psychosis (CBTp) for schizophrenia: literature review and meta-analysis//Int. J. Cogn. Ther. 2016. Vol. 9, N 1. P. 73 - 86.

213. Tai S., Turkington D. The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments//Schizophr. Bull. 2009. Vol. 35, N 5. P. 865 - 873.

214. Breitborde N.J.K., Moe A.M., Ered A., Ellman L.M., Bell E.K. Optimizing psychosocial interventions in first episode psychosis: current perspectives and future directions//Psychol. Res. Behav. Management. 2017. Vol. 10. P. 119 - 128.

215. Костюкова А.Б., Мосолов С.Н. Нейровоспалительная гипотеза шизофрении и некоторые новые терапевтические подходы//Современная терапия психических расстройств. 2013, N 4, с. 2 - 8.

216. Мосолов С.Н., Калинин В.В., Сулимов Г.Ю. и соавт. Сравнительная эффективность и переносимость нового поколения атипичных антипсихотиков при обострениях параноидной шизофрении (мета-анализ оригинальных исследований оланзапина, рисперидона и кветиапина)//Социальная и клиническая психиатрия. - 2001. - Т. 11, N 2. - С. 59 - 65.

217. Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.//J Clin Psychiatry 2004; 65: 551-6.

218. Мосолов С.Н. Некоторые актуальные теоретические проблемы диагностики, классификации, нейробиологии и терапии шизофрении: сравнение зарубежного и отечественного подходов.//Журнал неврологии и психиатрии им. С.С. Корсакова. - 2010, Т. 110, N 6, С. 4 - 11.

219. Мосолов С.Н., Кузавкова М.В., Калинин В.В., Еремин А.В., Сулимов Г.Ю. Анализ влияния атипичных антипсихотиков на 5-факторную модель шизофрении//Социальная и клиническая психиатрия. 2003, Т. 13, N 3, С. 45 - 52.

220. Мосолов С.Н., Потапов А.В., Шафаренко А.А., Костюкова А.Б., Ушаков Ю.В., Бурыгина Л.А., Забелина И.Н. Разработка и валидизация стандартизированных критериев терапевтической ремиссии при шизофрении.//Современная терапия психических расстройств. 2011. N 3. С. 2 - 6.

221. Promethazine: off label uses. [Электронныи ресурс]. URL: https://www.drugs.com/pro/promethazine.html (дата обращения 28.02.2021)

222. Ketamine: off label uses. [Электронныи ресурс]. URL: https://www.drugs.com/ppa/ketamine.html (дата обращения 28.02.2021)

223. Diphenhydramine off label uses. [Электронныи ресурс]. URL: https://www.drugs.com/pro/diphenhydramine.html#s-34067-9 (дата обращения 28.02.2021)

224. Propranolol: doses and off label uses. [Электронныи ресурс]. URL: https://www.drugs.com/condition/akathisia.html (дата обращения 28.02.2021)

225. Инструкция по применению зуклопентиксола. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d9e1cf58-46c8-4274-9680-7a025ba1841e&t= (дата обращения 28.02.2021)

226. Инструкция по применению флуфеназина-деканоата. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e6b6dad3-8a01-4847-95d9-bcdb41fed6b3&t= (дата обращения 28.02.2021)

227. Инструкция по применению дроперидола. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=75fe9e69-d6ee-47d7-a631-d48b0273eadc&t= (дата обращения 28.02.2021)

228. Инструкция по применению перициазина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=061ff477-f207-4d32-a0dc-878648b5cc43&t= (дата обращения 28.02.2021)

229. Инструкция по применению перфеназина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=567b21ce-8e9a-4784-bbff-d4379cbb6453&t= (дата обращения 28.02.2021)

230. Инструкция по применению тиаприда. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=548ec162-d811-4ab9-bd4e-c37d55b8802d&t= (дата обращения 28.02.2021)

231. Инструкция по применению трифлуоперазина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ddbbc53d-fa7e-4e7e-af4b-d3f1db7341c2&t= (дата обращения 28.02.2021)

232. Инструкция по применению флупентиксола. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=23ada517-70ac-4676-bf66-b62e7e92c5e2&t= (дата обращения 28.02.2021)

233. Инструкция по применению тиоридазина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=38fc99ea-76e8-40d5-8027-e13867a6bcc0&t= (дата обращения 28.02.2021)

234. Инструкция по применению хлорпротиксена. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=4c03b43e-a2d6-433b-b87d-090708961ac4&t= (дата обращения 28.02.2021)

235. Инструкция по применению хлорпромазина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=6027ccd6-57f9-4ff0-bbf4-124ec10974fe&t= (дата обращения 28.02.2021)

236. Инструкция по применению клозапина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ac7f56b3-2434-4153-9ec9-4d76acf5e9fc&t= (дата обращения 28.02.2021)

237. Инструкция по применению левомепромазина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=29132366-97a8-49b6-9a2d-b76f9f864be9&t= (дата обращения 28.02.2021)

238. Инструкция по применению тригексифенидила. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=53fd34f1-74ea-472b-a883-dee216bccb11&t= (дата обращения 28.02.2021)

239. Инструкция по применению биперидена. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fc4d08ee-6d72-487e-a3ff-2c1d31d18f12&t= (дата обращения 28.02.2021)

240. Инструкция по применению бромдигидрохлорфенилбензодиазепина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c97666bc-acd3-4d8d-891b-1ab43e0b9813&t= (дата обращения 28.02.2021)

241. Инструкция по применению диазепама. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=91047b3f-f555-478d-862a-7a230a0aaef6&t= (дата обращения 28.02.2021)

242. Инструкция по применению мидазолама. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cd2f7ae2-b22f-4b00-ad50-189556897f56&t= (дата обращения 28.02.2021)

243. Инструкция по применению алпразолама. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4d5bf31-9f18-49d3-951b-f047b37f8106&t= (дата обращения 28.02.2021)

244. Инструкция по применению клоназепама. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5cb92ffd-47fb-4e4c-91ff-c3907e469f21&t= (дата обращения 28.02.2021)

245. Инструкция по применению лоразепама. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=63dcb296-9fae-434e-b54d-8c28052c77fa&t= (дата обращения 28.02.2021)

246. Инструкция по применению эсциталопрама. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=73f4317b-f057-49a5-b3b9-2966331fe49b&t= (дата обращения 28.02.2021)

247. Инструкция по применению имипрамина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=66318a20-01a2-4698-9507-68653df05036&t= (дата обращения 28.02.2021)

248. Инструкция по применению амитриптилина. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d275ba62-d57d-4b2d-9928-24285cd36320&t= (дата обращения 28.02.2021)

249. Venlafaxine Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/dosage/venlafaxine.html (дата обращения 28.02.2021)

250. Haloperidol Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=haloperidol&a=1 (дата обращения 28.02.2021)

251. Risperidone Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=risperidone&a=1 (дата обращения 28.02.2021)

252. Aripiprazole Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=aripiprazole&a=1 (дата обращения 28.02.2021)

253. Quetiapine Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=quetiapine&a=1 (дата обращения 28.02.2021)

254. Olanzapine Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=olanzapine&a=1 (дата обращения 28.02.2021)

255. Paliperidone Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=paliperidone&a=1 (дата обращения 28.02.2021)

256. Инструкция по применению амисульприда. [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d48f7ec2-6683-4fe9-a2c9-f36a1ee8d60a&t= (дата обращения 28.02.2021)

257. Инструкция по применению дексмедетомидина [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c7a4ea74-633e-414b-95e7-58fbc187c99e&t= (дата обращения 28.02.2021)

258. Инструкция по применению карипразина [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3a7c2f32-f659-4fdb-9d5c-f15f8f6b5c52&t= (дата обращения 28.02.2021)

259. Инструкция по применению зипрасидона [Электронныи ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d7d8bd2c-6b6d-4db0-9a1e-2f674cd201d6&t= (дата обращения 28.02.2021)

260. Mirtazapine Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=mirtazapine&a=1 (дата обращения 28.02.2021)

261. Mianserine Dosage and off-label uses. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=mianserin (дата обращения 28.02.2021)

262. Memantine Dosage. [Электронныи ресурс]. URL: https://www.drugs.com/search.php?searchterm=memantine&a=1 (дата обращения 28.02.2021)

263. Galantamine: Dosage and off-label uses. [Электронныи ресурс]. URL: https://www.drugs.com/pro/galantamine-capsules.html#s-34068-7 (дата обращения 28.02.2021)

264. Valproic acid: Dosage and off-label uses. [Электронныи ресурс]. URL: https://www.drugs.com/ppa/valproic-acid-and-derivatives.html (дата обращения 28.02.2021)

265. Carbamazepine: Dosage and off-label uses. [Электронныи ресурс]. URL: https://www.drugs.com/ppa/carbamazepine.html (дата обращения 28.02.2021)

266. Lithium Carbonate: Dosage and off-label uses. [Электронныи ресурс]. URL: https://www.drugs.com/pro/lithium.html#s-34067-9 (дата обращения 28.02.2021)

267. Папсуев О.О., Мовина Л.Г., Гладышев И.О., Шмуклер А.Б. Психометрические свойства русскоязычной версии краткой шкалы оценки негативных симптомов (BNSS) у пациентов с шизофренией и расстройствами шизофренического спектра//Социальная и клиническая психиатрия. 2020. Т. 30. N 2. С. 22 - 30.

268. Mucci A., Vignapiano A., Bitter I., Austin S.F., Delouche C., Dollfus S., Erfurth A., Fleischhacker W.W., Giordano G.M., Gladyshev I., Glenth j B., G tter K., Hofer A., Hube k J., Kaiser S., Libiger J., Melle I., Nielsen M.., Papsuev O., Rybakowski J.K., Sachs G., ok A., Wojciak P., Galderisi S. A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. Eur Neuropsychopharmacol. 2019 Aug; 29(8): 947-959. doi: 10.1016/j.euroneuro.2019.05.006. Epub 2019 Jun 27. PMID: 31255394.

269. Kirkpatrick B., Strauss G.P., Nguyen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011 Mar; 37(2): 300-5. doi: 10.1093/schbul/sbq059. Epub 2010 Jun 17. PMID: 20558531; PMCID: PMC3044634.

270. Психиатрическая помощь больным шизофренией. Клиническое руководство (второе издание) (под ред. В.Н. Краснова, И.Я. Гуровича, С.Н. Мосолова, А.Б. Шмуклера) - М.: ИД "МЕДПРАКТИКА-Мю" - 2007. - 260 с.

271. Watanabe J. et al. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour Holter electrocardiogram recording study//Journal of clinical psychopharmacology. - 2012. - Т. 32. - N. 1. - С. 18 - 22.

272. Kishimoto T. et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics//Molecular Psychiatry. - 2013. - Т. 18. - N. 1. - С. 53 - 66.

273. Zhang J. P. et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis//International Journal of Neuropsychopharmacology. - 2013. - Т. 16. - N. 6. - С. 1205 - 1218.

274. Zhu Y. et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses//The Lancet Psychiatry. - 2017. - Т. 4. - N. 9. - С. 694 - 705.

275. Siskind D., Siskind V., Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis//The Canadian Journal of Psychiatry. - 2017. - Т. 62. - N. 11. - С. 772 - 777.

276. Meltzer H. Y. et al. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT)//Archives of general psychiatry. - 2003. - Т. 60. - N. 1. - С. 82 - 91.

277. Larsen J. R. et al. High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine //CNS spectrums. - 2019. - Т. 24. - N. 4. - С. 441 - 452.

278. Gautam S., Meena P. S. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics//Indian journal of psychiatry. - 2011. - Т. 53. - N. 2. - С. 128.

279. Fric M., Laux G. Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine //Psychiatrische Praxis. - 2003. - Т. 30. - N. Suppl 2. - С. 97 - 101.

280. Montgomery J. et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment//Journal of Clinical Psychiatry. - 2004. - Т. 65. - N. 11. - С. 1491 - 1498.

281. Harrigan E. P. et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition //Journal of clinical psychopharmacology. - 2004. - Т. 24. - N. 1. - С. 62 - 69.

282. Nielsen J. et al. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia//European Neuropsychopharmacology. - 2015. - Т. 25. - N. 3. - С. 303-311.

283. Uchida H. et al. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis//Schizophrenia bulletin. - 2011. - Т. 37. - N. 4. - С. 788 - 799.

284. Dudley K., Liu X., De Haan S. Chlorpromazine dose for people with schizophrenia//Cochrane Database of Systematic Reviews. - 2017. - N. 4.

285. Hong C. J., Chen J. Y., Sim C. B. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia//International clinical psychopharmacology. - 1997.

286. Josiassen R. C. et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial//American Journal of Psychiatry. - 2005. - Т. 162. - N. 1. - С. 130 - 136.

287. Muscatello M. R. A. et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study//Schizophrenia research. - 2011. - Т. 127. - N. 1-3. - С. 93 - 99.

288. Huf G. et al. Haloperidol plus promethazine for psychosis induced aggression//Cochrane Database of Systematic Reviews. - 2016. - N. 11.

289. Johnson D. A. Long-term maintenance treatment in chronic schizophrenia: Some observations on outcome and duration//Acta Psychiatrica Belgica. - 1981.

290. Rzewuska M. Drug maintenance treatment compliance and its correlation with the clinical picture and course of schizophrenia//Progress in Neuro-Psychopharmacology and Biological Psychiatry. - 2002. - Т. 26. - N. 4. - С. 811 - 814.

291. Gaebel W. et al. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia//The Journal of clinical psychiatry. - 2010. - Т. 72. - N. 2. - С. 205 - 218.

292. Kim H. O., Seo G. H., Lee B. C. Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia//Annals of general psychiatry. - 2020. - Т. 19. - N. 1. - С. 1-7.

293. Magliocco F. et al. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study//International journal of psychiatry in clinical practice. - 2020. - Т. 24. - N. 2. - С. 201 - 207.

294. Gonz lez-Rodr guez A. et al. Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability-a review//Patient preference and adherence. - 2015. - Т. 9. - С. 695.

295. Bai Y. M. et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study//Pharmacopsychiatry. - 2006. - Т. 39. - N. 04. - С. 135 - 141.

296. Beach, S. R., Gross, A. F., Hartney, K. E., Taylor, J. B., & Rundell, J. R. (2020). Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use. General Hospital Psychiatry. doi: 10.1016/j.genhosppsych.2020.08.008.

297. Bigal, M. E., Bordini, C. A., & Speciali, J. G. (2002). Intravenous chlorpromazine in the Emergency Department treatment of migraines: a randomized controlled trial. The Journal of Emergency Medicine, 23(2), 141 - 148. doi: 10.1016/s0736-4679(02) 00502-4.

298. Stenberg JH, Terevnikov V, Joffe M, Tiihonen J, Tchoukhine E, Burkin M, et al. Effects of add on mirtazapine on neurocognition in schizophrenia: A double blind, randomized, placebo controlled study. International Journal of Neuropsychopharmacology 2010; 13(4): 433 441.

299. Poyurovsky M., Koren D., Gonopolsky I., Schneidman M., Fuchs C., Weizman A., Weizman R. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003 Mar; 13(2): 123-128.

300. Kramer M., Gorkin R., DiJohnson C., Sheves P. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. Biol Psychiatry. 1988 Nov; 24(7): 823 - 827.

301. Terao T., Oga T., Nozaki S., Ohta A., Ohtsubo Y., Yamamoto S., Zamami M., Okada M. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double blind, placebo controlled, cross over study. Acta Psychiatrica Scandinavica 1995; 92: 220 224.

302. Estorges J., Llorca P., Lancon C., Bougerol T., Scotto J. Carbamazepine as adjuvant treatment to neuroleptics in schizophrenic patients. Encephale 1991; 17(4): 307.

303. Casey D., Daniel D., Tamminga C., Kane J., Tran Johnson T., Wozniak P., et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009; 34(5): 1330 8.

304. Calver L., Drinkwater V., Gupta R., Page C., Isbister G. Droperidol vs haloperidol for sedation of aggressive behaviour in acute mental health: randomized controlled trial. British Journal of Psychiatry 2015; 206(3): 223 228.

305. Karia S., Shah N., De Sousa A., Sushma S. Tiapride for the Treatment of Auditory Hallucinations in Schizophrenia. Indian Journal of Psychological Medicine 2013 35(4): 397-399.

306. Stroebel C., Szarer B., Grueck B. Use of clomipramine in the treatment of obsessive-compulsive symptoms. J. Clin. Psychopharmacotherapy. 1984; 4: 98 - 100.

307. Zisook S., Kasckow J., Golshan S. at al. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial Clin Psychiatry. 2009; 70(4): 562-571. doi: 10.4088/jcp.08m04261.

308. Lindenmayer J.P., Vakharia M., Kanofsky D. Fluoxetine in chronic schizophrenia. J.Clin Psychopharmacol. 1990; 10(1): 76. doi: 10.1097/00004714-199002000-00031.

309. Zheng W., Xiang Y.-O., Cai D-B at al. Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials. J. Clin Psychopharmacol 2020; 40(4): 386 - 390. doi: 10.1097/JCP.0000000000001245.

310. Mulholland C., Lynch G., King A., Cooper S. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J. Med Sci, 2020; 36(3): 516-520.

311. Wang N., Zheng N., Dong M., He J. Paroxetine combined with olanzapine in the treatment of schizophrenia Pak J Med Sci. 2020 Mar-Apr; 36(3): 516-520.

312. Wang Y., Xia J., Helfer B., Li C., Leucht S. Valproate for schizophrenia. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD004028.

313. Leucht S., Helfer B., Dold M., Kissling W., McGrath J. Carbamazepine for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD001258.